---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-081717"
form_type: "8-K"
ticker: "KNSA"
cik: "0001730430"
company_name: "Kiniksa Pharmaceuticals International, plc"
filed_at: "2024-07-23T23:59:59+00:00"
generated_at: "2026-05-31T18:08:42.402832+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Kiniksa Q2 ARCALYST revenue $103.4M (+90% YoY); 2024 guidance raised to $405-415M

## Summary
- ARCALYST net product revenue $103.4M in Q2 2024, up 90% YoY; ~11% of target 14,000 patients on therapy.
- Total revenue $108.6M (Q2 2024) vs $71.5M (Q2 2023); net loss $3.9M vs net income $15.0M YoY.
- 2024 ARCALYST net revenue guidance increased to $405-415M from prior $370-390M.
- Cash and investments $218.8M, no debt; expects to remain cash flow positive annually.
- Phase 2b trial of abiprubart in Sjögren's Disease enrolling; clinical development fully funded.

## SEC filing metadata
- accession: 0001104659-24-081717
- form_type: 8-K
- ticker: KNSA
- cik: 0001730430
- company_name: Kiniksa Pharmaceuticals International, plc
- filed_at: 2024-07-23T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730430/000110465924081717/0001104659-24-081717-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730430/000110465924081717/tm2419915d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-081717
- JSON: https://secwatch.observer/filing/0001104659-24-081717.json
- Plain text: https://secwatch.observer/filing/0001104659-24-081717.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.